ANI Pharmaceuticals Inc (ANIP) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.
Total Assets Chart for ANI Pharmaceuticals Inc
ANI Pharmaceuticals Inc (ANIP) total assets for FY2025 were USD 1.4B, a 12.2% change from FY2024. ANI Pharmaceuticals Inc's total assets grew from USD 3.4M in 1998 to USD 1.4B in 2025 (41658.0% over 27 years). Total assets compound annual growth rate: 5-year CAGR of 25.6%, 10-year CAGR of 17.6%, 20-year CAGR of 28.5%.
Total Assets (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $1.66B
- Implied Share Price
- $72.32
- Enterprise Value
- $1.94B
- Revenue (TTM)
- $978.38M
- EBITDA
- $209.41M
- Profit Margin
- 11.07%
- Trailing P/E
- 15.65
- Forward P/E
- 7.12
- Price/Book (MRQ)
- 2.86
- Price/Sales (TTM)
- 1.70
- EV/EBITDA
- 7.94
- EV/Revenue
- 1.99
- Dividend Yield
- —
- Book Value
- $27.87
- Free Cash Flow (FY2025)
- $150.90M
- Free Cash Flow Yield
- 9.09%
Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.